Literature DB >> 17075814

Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.

Eugene Y Kissin1, Peter A Merkel, Robert Lafyatis.   

Abstract

OBJECTIVE: To investigate the correlation between the degree of dermal fibrosis and myofibroblast infiltration using clinical assessments of skin thickness and hardness in systemic sclerosis (SSc).
METHODS: Eleven patients with diffuse SSc and 10 healthy controls were evaluated using the modified Rodnan skin thickness score and durometry (hardness measurement). Biopsy samples were obtained from the dorsal mid-forearm in all subjects at the baseline visit and again 6-12 months later in patients with SSc. Five of the patients with SSc received treatment with cyclophosphamide (CYC) in the interval between skin biopsies. Biopsy sections were assessed for myofibroblast and hyalinized collagen content by 2 blinded observers.
RESULTS: Myofibroblast and hyalinized collagen scores each correlated with the forearm skin score (r = 0.83, P < 0.0001 and r = 0.78, P < 0.0001, respectively) and with the forearm durometry score (r = 0.72, P < 0.0004 and r = 0.69, P < 0.0008, respectively). The change in the dermal hyalinized collagen score correlated with the change in the forearm durometry score (r = 0.74, P < 0.0213). The myofibroblast score decreased in all 5 patients who received CYC and increased in those receiving non-CYC treatments (P < 0.01 for the difference).
CONCLUSION: Myofibroblasts play an important role in the pathogenesis of fibrosis, and our data imply that quantification of myofibroblasts and hyalinized collagen in skin may be a useful outcome measure in clinical studies of SSc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075814     DOI: 10.1002/art.22186

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  46 in total

Review 1.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

2.  An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.

Authors:  Flavia V Castelino; Gretchen Bain; Veronica A Pace; Katharine E Black; Leaya George; Clemens K Probst; Lance Goulet; Robert Lafyatis; Andrew M Tager
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

3.  Sustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes.

Authors:  Emily Hamburg-Shields; Gregg J DiNuoscio; Nathaniel K Mullin; Robert Lafyatis; Radhika P Atit
Journal:  J Pathol       Date:  2015-01-07       Impact factor: 7.996

4.  Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.

Authors:  Remedios Castello-Cros; Diana Whitaker-Menezes; Alex Molchansky; George Purkins; Louis J Soslowsky; David P Beason; Federica Sotgia; Renato V Iozzo; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

5.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

6.  Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.

Authors:  Banafsheh Nazari; Lisa M Rice; Giuseppina Stifano; Alexander M S Barron; Yu Mei Wang; Tess Korndorf; Jungeun Lee; Jag Bhawan; Robert Lafyatis; Jeffrey L Browning
Journal:  Am J Pathol       Date:  2016-08-23       Impact factor: 4.307

7.  B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Authors:  Robert Lafyatis; Eugene Kissin; Michael York; Giuseppina Farina; Kerry Viger; Marvin J Fritzler; Peter A Merkel; Robert W Simms
Journal:  Arthritis Rheum       Date:  2009-02

8.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

9.  The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

Authors:  Yoshihito Shima; Yusuke Kuwahara; Hiroyuki Murota; Shun Kitaba; Mari Kawai; Toru Hirano; Junsuke Arimitsu; Masashi Narazaki; Keisuke Hagihara; Atsushi Ogata; Ichiro Katayama; Ichiro Kawase; Tadamitsu Kishimoto; Toshio Tanaka
Journal:  Rheumatology (Oxford)       Date:  2010-09-05       Impact factor: 7.580

Review 10.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.